دورية أكاديمية
أعرض في EDS

Single-cell landscape reveals the immune heterogeneity of bone marrow involvement in peripheral T-cell lymphoma.

التفاصيل البيبلوغرافية
العنوان: Single-cell landscape reveals the immune heterogeneity of bone marrow involvement in peripheral T-cell lymphoma.
المؤلفون: Liu J; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Precision Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China., Xia B; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Jiang X; Department of Lymphoma, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Cao L; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Xi Z; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Liang L; Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China., Zhang S; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhang H; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China., Li W; Medical Research institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Lymphoma, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
المصدر: Cancer science [Cancer Sci] 2024 Aug; Vol. 115 (8), pp. 2540-2552. Date of Electronic Publication: 2024 Jun 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : Oxford : Wiley Publishing on behalf of the Japanese Cancer Association
Original Publication: Tokyo : Japanese Cancer Association, c2003-
مواضيع طبية MeSH: Lymphoma, T-Cell, Peripheral*/immunology , Lymphoma, T-Cell, Peripheral*/genetics , Lymphoma, T-Cell, Peripheral*/pathology , Single-Cell Analysis* , Tumor Microenvironment*/immunology , Tumor Microenvironment*/genetics , Bone Marrow*/pathology , Bone Marrow*/immunology, Humans ; Male ; Female ; Prognosis ; Middle Aged ; Aged ; Mutation ; Receptors, Antigen, T-Cell/genetics ; rhoA GTP-Binding Protein/genetics ; Adult ; Genetic Heterogeneity
مستخلص: The prognosis of patients with peripheral T-cell lymphoma (PTCL) depends on bone marrow involvement (BMI). The bone marrow (BM) tumor microenvironment in PTCL remains unclear. We performed single-cell RNA sequencing (scRNA-seq) on 11 fresh BM samples from patients with BMI to reveal the associations of immune landscape and genetic variations with the prognosis of PTCL patients. Compared with PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL) had a higher number of T cells, lower number of lymphocytes, and greater inflammation. Immune heterogeneity in AITL is associated with prognosis. In particular, specific T-cell receptor (TCR) T cells are enriched in patients with good response to anti-CD30 therapy. We observed RhoA mutation-associated neoantigens. Chidamide-treated patients had a higher number of CD4+ regulatory cells and a better treatment response compared with other patients. In the nonresponder group, T-cell enrichment progressed to secondary B-cell enrichment and subsequently diffuse large B-cell lymphoma. Moreover, AITL patients with lymphoma-associated hemophagocytic syndrome had more T follicular helper (Tfh) cells with copy number variations in CHR5. To our knowledge, this study is the first to reveal the single-cell landscape of BM microenvironment heterogeneity in PTCL patients with BMI. scRNA-seq can be used to investigate the immune heterogeneity and genetic variations in AITL associated with prognosis.
(© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
References: Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):687-691. (PMID: 30017596)
Blood. 2015 Oct 8;126(15):1741-52. (PMID: 26268241)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Nat Genet. 2014 Feb;46(2):166-70. (PMID: 24413734)
Nat Genet. 2014 Feb;46(2):171-5. (PMID: 24413737)
Nat Rev Cardiol. 2020 Aug;17(8):457-473. (PMID: 32231331)
Mol Cell. 2019 Jul 11;75(1):7-12. (PMID: 31299208)
Blood. 2007 Jun 1;109(11):4952-63. (PMID: 17284527)
PLoS Pathog. 2020 Feb 26;16(2):e1008334. (PMID: 32101596)
Nat Commun. 2017 Jan 16;8:14049. (PMID: 28091601)
Cancer Res. 2007 Nov 15;67(22):10703-10. (PMID: 18006812)
Annu Rev Immunol. 2010;28:445-89. (PMID: 20192806)
PLoS One. 2014 Mar 20;9(3):e92585. (PMID: 24651162)
Blood. 2005 Aug 15;106(4):1501-2. (PMID: 16079436)
Blood. 2010 Feb 4;115(5):1026-36. (PMID: 19965671)
Nat Genet. 2014 Apr;46(4):371-5. (PMID: 24584070)
Curr Opin Hematol. 2007 Jul;14(4):348-53. (PMID: 17534160)
Clin Nucl Med. 2019 May;44(5):e336-e341. (PMID: 30889000)
Ann Oncol. 2002 Jan;13(1):140-9. (PMID: 11863096)
Hematol Oncol. 2008 Sep;26(3):152-8. (PMID: 18395866)
J Clin Oncol. 2013 Jan 10;31(2):240-6. (PMID: 22869878)
Cell. 2019 Oct 31;179(4):829-845.e20. (PMID: 31675496)
J Clin Oncol. 2008 Sep 1;26(25):4124-30. (PMID: 18626005)
Blood. 2014 Feb 27;123(9):1293-6. (PMID: 24345752)
Br J Haematol. 2006 Jul;134(1):45-53. (PMID: 16803566)
F1000Res. 2020 Jan 27;9:47. (PMID: 32789006)
J Clin Exp Hematop. 2021 Jun 5;61(2):61-70. (PMID: 33716242)
Diagn Pathol. 2012 Jan 19;7:7. (PMID: 22260632)
Blood. 2018 Apr 19;131(16):1809-1819. (PMID: 29449276)
Cancer Immunol Res. 2020 Mar;8(3):409-420. (PMID: 31907209)
Ann Hematol. 2015 Feb;94(2):239-47. (PMID: 25193354)
Curr Oncol. 2021 Dec 20;28(6):5480-5498. (PMID: 34940095)
Cancer Sci. 2024 Aug;115(8):2540-2552. (PMID: 38845192)
Cell Syst. 2019 Apr 24;8(4):329-337.e4. (PMID: 30954475)
Cancers (Basel). 2021 Sep 09;13(18):. (PMID: 34572763)
Rev Bras Hematol Hemoter. 2012;34(1):42-7. (PMID: 23049383)
Cell. 2019 Jun 13;177(7):1888-1902.e21. (PMID: 31178118)
Leuk Lymphoma. 2013 May;54(5):1004-11. (PMID: 22971239)
Clin Nucl Med. 2019 Jan;44(1):4-10. (PMID: 30371574)
Nat Genet. 2015 Nov;47(11):1304-15. (PMID: 26437031)
Ann Hematol. 2016 Jan;95(2):245-51. (PMID: 26537613)
Nat Rev Immunol. 2018 Jan;18(1):35-45. (PMID: 28787399)
Curr Hematol Malig Rep. 2018 Aug;13(4):318-328. (PMID: 29951889)
Blood. 2016 Sep 15;128(11):1490-502. (PMID: 27369867)
معلومات مُعتمدة: DFJH2020025 Guangdong Province High-level Hospital Construction Project of Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences; KJ012019376 Talent Research Funding Project of Guangdong Provincial People's Hospital; 81730060 Important Key Program of the Natural Science Foundation of China; 92169201 Important Key Program of the Natural Science Foundation of China; 92369205 Important Key Program of the Natural Science Foundation of China; 82150710553 Exchange Program of the Natural Science Foundation of China; 2022YFC0870700 National Key R&D Program of Department of Science and Technology of China; EKPG21-24 Emergency Key Program of Guangzhou National Laboratory; 2022B1111020004 Key R&D Program of Department of Science and Technology of Guangdong
فهرسة مساهمة: Keywords: angioimmunoblastic T‐cell lymphoma; genetic variation; immune heterogeneity; peripheral T‐cell lymphoma; single‐cell RNA sequencing; tumor microenvironment
المشرفين على المادة: 0 (Receptors, Antigen, T-Cell)
EC 3.6.5.2 (rhoA GTP-Binding Protein)
124671-05-2 (RHOA protein, human)
تواريخ الأحداث: Date Created: 20240607 Date Completed: 20240809 Latest Revision: 20240811
رمز التحديث: 20240812
مُعرف محوري في PubMed: PMC11309951
DOI: 10.1111/cas.16227
PMID: 38845192
قاعدة البيانات: MEDLINE
الوصف
تدمد:1349-7006
DOI:10.1111/cas.16227